Table III.
Role of m6A in the pathological stage and poor prognosis of pancreatic cancer.
| Initiation factor | Oncogenicity/suppressor | Signaling or target | Effect | (Refs.) |
|---|---|---|---|---|
| METTL3 | Oncogenicity↑ | Pathological stage Poor prognosis↑ |
(103) | |
| CSC-METTL3↑-miR-25-3p↑-PHLPP2↓-AKT-p70S6K↑ | Poor prognosis↑ | (84) | ||
| WTAP | Oncogenicity↑ | WTAP↑- mRNA↑ | Poor prognosis↑ | (104) |
| FTO | Suppressor↓ | FTO↓-YTHDF2-PJA2↓-Wnt signaling↑ | Pathological stage Poor prognosis↓ |
(89) |
| ALKBH5 | Suppressor↓ | ALKBH5↓-PER1↓-ATM-CHK2-P53/CDC25C↓ | Poor prognosis↓ | (91) |
| ALKBH5↓-WIF-1↓-Wnt signaling↑ | Poor prognosis↓ | (94) | ||
| ALKBH5↓-FBXL5↓-degradation↓ | Poor prognosis↓ | (95) | ||
| YTHDF2 | Oncogenicity↑ | YTHDF2↑-YAP↓ | Pathological stage Poor prognosis↑ |
(105) |
| IGF2BP2 | Oncogenicity↑ | IGF2BP2↑-DANCR↑ | Poor prognosis↑ | (96) |
| IGF2BP2↑-mRNA GLUT1↑ | Poor prognosis↑ | (111) | ||
| IGF2BP2↑-protein IMP2↑ | Poor prognosis↑ | (107) | ||
| LINC00857 | Oncogenicity↑ | LINC00857↑-miR-150-5p↓-E2F3↑ | Poor prognosis↑ | (97) |
| CLK1↑□ | Phosphorylationon SRSF5250-Ser↑ |
METTL14exon 10skipping↓ | Pathological stage Poor prognosis↑ |
(108) |
| Cyclin L2exon6.3skipping↑ | (108) | |||
| Structural | HNRNPC | TAF8L↓ | Pathological stage | (109) |
| switch | TAF8S↑ | Poor prognosis↑ | (109) |
'↑' represents upregulation and '↓' represents downregulation. CSC, cigarette smoke condensate; PJA2, praja ring finger ubiquitin ligase 2; METTL, methyltransferase-like protein; WTAP, Wilms' tumor 1-associating protein; RBM15, RNA-binding motif protein 15; CLK1, Cdc2-like kinase 1; FTO, fat mass and obesity-associated protein; ALKBH5, alkB homolog 5, RNA demethylase; YTHDC, YT521-B homology domain-containing protein; HNRN, heterogeneous nuclear ribonucleoprotein; IGF2BPS, insulin-like growth factor-2 mRNA-binding proteins; YTHDF, YTH N6 methyladenosine RNA binding protein.